Follow
Daniel Farrugia
Daniel Farrugia
University of Pittsburgh Medical Center
Verified email at mail.magee.edu
Title
Cited by
Cited by
Year
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
W Sakai, EM Swisher, BY Karlan, MK Agarwal, J Higgins, C Friedman, ...
Nature 451 (7182), 1116-1120, 2008
11682008
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells
M Taniai, A Grambihler, H Higuchi, N Werneburg, SF Bronk, DJ Farrugia, ...
Cancer research 64 (10), 3517-3524, 2004
2702004
Functional evaluation and cancer risk assessment of BRCA2 unclassified variants
K Wu, SR Hinson, A Ohashi, D Farrugia, P Wendt, SV Tavtigian, ...
Cancer research 65 (2), 417-426, 2005
1632005
Functional assays for classification of BRCA2 variants of uncertain significance
DJ Farrugia, MK Agarwal, VS Pankratz, AM Deffenbaugh, D Pruss, C Frye, ...
Cancer research 68 (9), 3523-3531, 2008
1342008
Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint
AB D'Assoro, R Busby, K Suino, E Delva, GJ Almodovar-Mercado, ...
Oncogene 23 (23), 4068-4075, 2004
852004
Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?
PK Lovelock, AB Spurdle, MTS Mok, DJ Farrugia, SR Lakhani, S Healey, ...
Breast Cancer Research 9, 1-13, 2007
702007
Low Estrogen Receptor (ER)–positive breast cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-positive or ER-negative disease?
A Landmann, DJ Farrugia, L Zhu, EJ Diego, RR Johnson, A Soran, ...
American journal of clinical pathology 150 (1), 34-42, 2018
652018
Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity
LC Walker, PJ Whiley, FJ Couch, DJ Farrugia, S Healey, DM Eccles, F Lin, ...
Human mutation 31 (6), E1484-E1505, 2010
652010
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors
DJ Farrugia, A Landmann, L Zhu, EJ Diego, RR Johnson, M Bonaventura, ...
Modern Pathology 30 (8), 1078-1085, 2017
392017
Impaired p53 function leads to centrosome amplification, acquired ERα phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts
AB D'assoro, R Busby, ID Acu, C Quatraro, MM Reinholz, DJ Farrugia, ...
Oncogene 27 (28), 3901-3911, 2008
392008
Improved breast cancer care quality metrics after implementation of a standardized tumor board documentation template
DJ Farrugia, TD Fischer, D Delitto, LRP Spiguel, CM Shaw
Journal of oncology practice 11 (5), 421-423, 2015
312015
Is completion axillary lymph node dissection necessary in patients who are underrepresented in the ACOSOG Z0011 trial?
BJ Gebhardt, J Thomas, ZD Horne, CE Champ, DJ Farrugia, E Diego, ...
Advances in Radiation Oncology 3 (3), 258-264, 2018
112018
HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?
A Landmann, DJ Farrugia, E Diego, M Bonaventura, A Soran, R Johnson, ...
Journal of Clinical Oncology 34 (15_suppl), 612-612, 2016
52016
Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER-disease?
A Landmann, DJ Farrugia, E Diego, A Soran, R Johnson, M Bonaventura, ...
Journal of Clinical Oncology 34 (15_suppl), 580-580, 2016
22016
Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer
BZ Clark, DJ Farrugia, A Landmann, EJ Diego, DJ Dabbs, SL Puhalla, ...
American Journal of Clinical Pathology 149 (4), 332-343, 2018
12018
Mitotic index to predict breast cancer recurrence after neoadjuvant systemic therapy.
DJ Farrugia, A Landmann, E Diego, PF McAuliffe, R Johnson, ...
Journal of Clinical Oncology 34 (15_suppl), e23265-e23265, 2016
12016
Macrocephaly and developmental delay caused by missense variants in RAB5C
K Koop, W Yuan, F Tessadori, WR Rodriguez-Polanco, J Grubbs, ...
Human molecular genetics 32 (21), 3063-3077, 2023
2023
High Ki-67 is associated with an increased likelihood of a pathologic complete response in patients with estrogen receptor positive breast cancer
JS Lee, EJ Diego, A Soran, DJ Farrugia, A Landmann, M Bonaventura, ...
ANNALS OF SURGICAL ONCOLOGY 24, 50-51, 2017
2017
Abstract P6-09-14: Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer
DJ Farrugia, A Landmann, PF McAuliffe, EJ Diego, R Johnson, ...
Cancer Research 77 (4_Supplement), P6-09-14-P6-09-14, 2017
2017
Prognostic significance of a modified residual disease in breast and nodes (mRDBN) algorithm after neoadjuvant therapy for breast cancer
DJ Farrugia, A Landmann, PF McAuliffe, EJ Diego, R Johnson, ...
CANCER RESEARCH 77, 2017
2017
The system can't perform the operation now. Try again later.
Articles 1–20